Your browser is no longer supported. Please, upgrade your browser.
Settings
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
TEVA [NYSE]
Teva Pharmaceutical Industries Limited
Index- P/E- EPS (ttm)-6.03 Insider Own2.70% Shs Outstand988.12M Perf Week-0.53%
Market Cap14.72B Forward P/E3.95 EPS next Y3.77 Insider Trans0.00% Shs Float912.42M Perf Month-13.12%
Income-6145.00M PEG- EPS next Q1.06 Inst Own60.00% Short Float4.89% Perf Quarter-54.11%
Sales23.37B P/S0.63 EPS this Y-96.10% Inst Trans-0.50% Short Ratio1.85 Perf Half Y-52.85%
Book/sh23.97 P/B0.62 EPS next Y-10.97% ROA-6.70% Target Price21.50 Perf Year-66.30%
Cash/sh0.62 P/C23.90 EPS next 5Y-6.90% ROE-21.20% 52W Range14.30 - 44.42 Perf YTD-58.90%
Dividend1.10 P/FCF6.07 EPS past 5Y-53.00% ROI1.10% 52W High-66.46% Beta0.56
Dividend %7.38% Quick Ratio0.60 Sales past 5Y3.60% Gross Margin50.60% 52W Low4.20% ATR0.63
Employees56960 Current Ratio0.90 Sales Q/Q12.90% Oper. Margin-18.10% RSI (14)37.96 Volatility3.19% 3.44%
OptionableYes Debt/Eq1.44 EPS Q/Q- Profit Margin-26.30% Rel Volume0.55 Prev Close14.93
ShortableYes LT Debt/Eq1.39 EarningsNov 02 BMO Payout- Avg Volume24.14M Price14.90
Recom2.90 SMA20-8.46% SMA50-10.52% SMA200-47.07% Volume13,292,310 Change-0.20%
Sep-21-17Reiterated Bernstein Mkt Perform $28 → $20
Sep-18-17Reiterated RBC Capital Mkts Underperform $21 → $15
Sep-11-17Upgrade BTIG Research Neutral → Buy
Aug-24-17Downgrade Credit Suisse Neutral → Underperform
Aug-16-17Downgrade Citigroup Buy → Neutral
Aug-07-17Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-04-17Downgrade RBC Capital Mkts Outperform → Underperform $37 → $21
Aug-04-17Downgrade Credit Suisse Outperform → Neutral
Aug-04-17Downgrade Bernstein Outperform → Mkt Perform
Aug-03-17Downgrade Oppenheimer Outperform → Perform
Jul-17-17Reiterated RBC Capital Mkts Outperform $38 → $37
Jun-16-17Upgrade Mizuho Neutral → Buy $25 → $30
Jun-16-17Initiated Cantor Fitzgerald Neutral $31
Feb-28-17Downgrade Argus Buy → Hold
Feb-13-17Reiterated Maxim Group Hold $41 → $40
Feb-10-17Downgrade Mizuho Buy → Neutral $40 → $27
Jan-31-17Upgrade BofA/Merrill Neutral → Buy
Jan-31-17Reiterated Barclays Equal Weight $46 → $38
Jan-20-17Downgrade JP Morgan Overweight → Neutral
Jan-09-17Downgrade Wells Fargo Outperform → Market Perform
Oct-22-17 08:02AM  Can Teva Pharmaceutical's Dividend Even Survive? Motley Fool
Oct-20-17 11:34PM  3-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
09:35AM  DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA ACCESSWIRE
Oct-19-17 05:30PM  DEADLINE MONDAY: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:32AM  EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Teva Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of October 23, 2017 ACCESSWIRE
09:50AM  Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Will Highlight New Data on Its MS Program at 7th joint ECTRIMS-ACTRIMS Meeting SmarterAnalyst
09:20AM  Teva Submits BLA to FDA for Migraine Candidate Fremanezumab Zacks
09:19AM  Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna Zacks
09:00AM  Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi Zacks
08:00AM  Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS ACTRIMS Congress in Paris Business Wire
07:51AM  3 Value Stocks for Retirees Motley Fool
Oct-18-17 04:30PM  Why SUPERVALU, Synchronoss Technologies, and Allergan Slumped Today Motley Fool
03:22PM  INVESTOR ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited GlobeNewswire
03:02PM  TEVA Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. Business Wire
02:55PM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
12:28PM  Shares of large generic drugmakers fall MarketWatch
12:19PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 TEVA ACCESSWIRE
Oct-17-17 07:33PM  Where to Find Value in Healthcare Stocks Zacks
02:02PM  DEADLINE ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:21AM  TEVA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Teva Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of October 23, 2017 ACCESSWIRE
10:00AM  3 Dividend Healthcare Stocks Motley Fool
09:47AM  Incoming Teva Pharm CEO Schultz to start by month end -newspaper Reuters
09:44AM  Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen Zacks
08:33AM  Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Submits Biologics License Application to the FDA for Migraine Treatment SmarterAnalyst
08:00AM  Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA Business Wire
Oct-16-17 04:42PM  Allergan Tanks After Judge Invalidates Restasis Patents Investor's Business Daily
03:20PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
11:01AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA ACCESSWIRE
Oct-14-17 09:10AM  DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Teva Pharmaceutical Industries Limited to Contact the Firm Business Wire
Oct-13-17 11:52PM  SHAREHOLDER REMINDER: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:50PM  TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - (TEVA) GlobeNewswire
04:04PM  PG&E, Teva Pharmaceuticals Dive into Fridays 52-Week Low Club 24/7 Wall St.
01:15AM  A New FDA Approval Sends Small Cap Flexion Soaring Motley Fool
12:35AM  Why Do Companies Pay Dividends? Motley Fool
Oct-12-17 05:23PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Teva Pharmaceutical Industries Ltd. To Contact The Firm ACCESSWIRE
04:04PM  JC Penney, General Electric Topple Into Thursdays 52-Week Low Club 24/7 Wall St.
02:30PM  BDSI settles patent litigation with generic giant Teva American City Business Journals
Oct-11-17 05:09PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
02:45PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA) Business Wire
11:37AM  The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (TEVA) ACCESSWIRE
10:55AM  Short Sellers Run for Cover From Major Pharma 24/7 Wall St.
07:20AM  Mylan Deals a Blow to Teva Pharmaceutical Motley Fool
Oct-10-17 01:50PM  UPCOMING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:43PM  Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 Business Wire
01:00PM  [$$] CVC Picks Former Allergan Executive to Run Women's Drug Portfolio The Wall Street Journal
11:07AM  TEVA EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Teva Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of October 23, 2017 ACCESSWIRE
Oct-09-17 01:31PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
10:25AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA ACCESSWIRE
10:20AM  Forget Teva (TEVA), Buy These 5 Drug Stocks Instead Zacks
Oct-08-17 04:29PM  Stocks That Fell to 3-Year Lows in the Week of Oct. 6 GuruFocus.com
Oct-07-17 01:45PM  DEADLINE APPROACHING: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:34AM  3 Drug Stocks That Soared This Week: Are They Buys? Motley Fool
Oct-06-17 10:50PM  TEVA PHARMACEUTICAL SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - (TEVA) Business Wire
07:00PM  Not His Cup of Teva; Recommended Reading: Best of Kass TheStreet.com
03:32PM  Motorola Solutions leading the IQ100 CNBC Videos
11:00AM  Is Allergan plc a Bargain After a $7.6 Billion Dip in September? Motley Fool
09:07AM  Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal Zacks
08:50AM  Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute Zacks
Oct-05-17 05:44PM  Mylan's FDA Approval Isn't All That: Wells Fargo Investopedia
02:04PM  Teva's Copaxone faces generic competition in Europe after U.S. hit Reuters
01:06PM  Celgene Is Not a Sell, Jim Cramer Rebuts Analysts' Call TheStreet.com
12:12PM  Teva Investors Concerned Debt Could Be Cut to Junk Rating TheStreet.com
11:16AM  Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early Zacks
10:40AM  Mylan: S&P 500s Top Gainer on October 4 Market Realist
09:35AM  Thursdays Vital Data: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Netflix, Inc. (NFLX) and JPMorgan Chase & Co. (JPM) InvestorPlace
09:18AM  Teva Announces tomys Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy Business Wire
08:39AM  Mylans surprise generic win sends Teva, Momenta shares plunging MarketWatch
08:20AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Mylan ACCESSWIRE
12:33AM  [$$] Even Tougher Choices Ahead for Teva After FDA Shocker The Wall Street Journal
12:28AM  Mylan surges, Teva slumps after FDA approves Copaxone copy Reuters
Oct-04-17 07:19PM  Cramer Remix: My mea culpa on DexCom and where its heade... CNBC Videos -14.56%
07:03PM  Cramer's lightning round: Why my charitable trust sold it... CNBC Videos
06:37PM  Shopify Drops After Citron Note; Verizon Is Protected From Yahoo Drama -- ICYMI TheStreet.com
05:02PM  What Happened in the Stock Market Today Motley Fool
04:52PM  The Hot Stock: My Oh Mylan! Barrons.com
04:14PM  Teva Dealt Another Blow With Latest Generic From Mylan, Outlook Remains Bleak TheStreet.com
04:11PM  How Mylan's MS-Generic Approval Caused Teva, Momenta To Plunge Investor's Business Daily
03:30PM  Teva Pharmaceutical Industries Ltd -- Moody's says approvals of generic versions of Copaxone are a credit positive for Mylan and a credit negative for Teva Moody's
02:35PM  Mylan And Teva And Copaxone, Explained Benzinga
02:34PM  Mylan surges, Teva slumps after FDA approves Copaxone copy Reuters
02:18PM  IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
02:15PM  Don't Be in a Hurry to Buy Teva Stock TheStreet.com
01:26PM  Mylan move is a bit exaggerated after FDA drug approval: ... CNBC Videos
01:21PM  Mylan N.V. (MYL) Stock Gets Massive Boost From Generic MS Drug Approval InvestorPlace
12:39PM  FDA approves Mylan generic MS treatment CNBC Videos
12:32PM  Today's charts: Mylan shares soar on FDA approval; Amazon hit with $295M fine; Netflix shares gain Yahoo Finance
12:28PM  A Generic Drug Face-Off Sends Mylan Soaring 19% Motley Fool
12:04PM  Mylan Is Now Worth $4 Billion More Because the FDA Approved This Generic Drug TheStreet.com
11:40AM  Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval Zacks
11:32AM  Mylan Stock Surges on FDA Approval of Generic Version of Teva's Copaxone TheStreet.com
11:21AM  The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (TEVA) ACCESSWIRE
11:15AM  [$$] US FDA approves generic competitor of Teva blockbuster drug Financial Times
10:58AM  Tesla revs higher, PepsiCo falls, Mylan soars Yahoo Finance
10:55AM  Teva shares down 13% following FDA approval of generic Copaxone American City Business Journals
10:43AM  [$$] Even Tougher Choices Ahead for Teva After FDA Shocker The Wall Street Journal
10:24AM  Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers TheStreet.com
09:56AM  The FDA just approved a 'complex generic drug' and it's sending one stock soaring and another crashing Business Insider
09:55AM  Teva: Yes, There's a Bright Side Barrons.com
09:33AM  Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg Zacks
09:26AM  Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL Business Wire
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson's disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. This segment also offers a portfolio of products in the women's health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products. The company has collaboration arrangements with Attenukine, Procter & Gamble Company, and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.